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chains from the ER to the cytosol (US2 and 11), or retain
class I molecules in the ER (US3). In another example,
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Weatherall Institute of Molecular Medicine class I expression on the surface of infected cells by
human immunodeficiency virus (HIV) nef protein (CollinsJohn Radcliffe Hospital
Headington, Oxford OX3 9DS et al., 1998). Nef can reroute the MHC class I molecules
to clathrin-coated pits for endosomal degradation,United Kingdom
which is dependent on a sequence motif in the cyto-
plasmic tail of the classical class I molecules (HLA-A
and HLA-B locus) (Le Gall et al., 1998). On the other
hand, HLA-C and HLA-E molecules that are able to bindMany viruses establish life-long infections in their nat-
to inhibitory receptors of natural killer (NK) cells do notural host with few if any clinical manifestations. The
contain this motif and are not downregulated by Nefrelationship between virus and host is a dynamic pro-
(Cohen et al., 1999). Thus, HIV-1 has evolved a strategycess in which the virus has evolved the means to coex-
aimed at selective elimination of class I expression thatist by reducing its visibility, while the host immune
avoids downregulation of those class I molecules whichsystem attempts to suppress and eliminate infection
inhibit NK cell killing.without damage to itself. This short review describes
Viral epitope mutation represents another way for aa variety of strategies that are employed by viruses to
virus escape from CTL and is probably of central impor-evade host immune responses. These include virus-
tance in HIV infection. Because HIV reverse tran-associated escape from T cell recognition, and resis-
scriptase is error prone, the high virus turnover continu-tance to apoptosis and counterattack, with special
ally generates many possible mutations. Under thereference to two papers published in this issue of Im-
pressure of CTL responses, viruses that contain mutatedmunity (Mueller et al., 2001; Raftery et al., 2001).
critical amino acids in epitopes recognized by CTL are
selected, provided the mutation is not harmful to theEscape
virus. Many studies have shown that mutational escapeIt is well established that control of virus infection by
of HIV-1 or SIV occurs during the course of infection inthe immune response normally requires virus-specific
patients or an animal model (reviewed in McMichael andcytotoxic T cells (CTL). CTL are primed by dendritic cells
Rowland-Jones, 2001).and other professional antigen presenting cells which
process viral proteins that are either endogenously pro-
duced or phagocytosed from apoptotic infected cells Resistance
Prolonging the survival of infected cells is clearly in the(crosspriming). Following clonal expansion, the primed
CTL can act against virus by killing infected cells via interest of infecting viruses, as it will allow full maturation
and dissemination. On the other hand, apoptosis of theperforin- and/or Fas-dependent pathways before new
virus particles are made. The killing takes less than 4 hr infected cells triggered by either immune attack or as
a direct outcome of viral infection is an important com-following CTL recognition of viral peptides presented
by MHC class I molecules at the surface of the infected ponent of the host antiviral response. Therefore, it is not
surprising that many viruses encode viral proteins thatcells. In parallel with this direct form of attack, CTL also
release cytokines and chemokines that have antiviral inhibit this process (Figure 1). There are two main path-
ways for induction of apoptotic cell death. One involvesactivity (reviewed in Guidotti and Chisari, 2001). To avoid
CTL attack, viruses have developed many tricks to en- death receptors on the cell surface (TNF receptor fam-
ily), TNF-R1, Fas, DR4, and DR5 by interaction with theirsure that the infected cells are not targeted by CTL.
These include interference with the peptide-presenting respective ligands TNF-, Fas ligand (FasL), and TRAIL.
The second pathway involves the participation of mito-pathway and viral epitope mutation.
For example, herpes simplex virus (HSV) establishes chondria and is regulated by members of Bcl-2 family
including the antiapoptotic molecules, bcl-2 or bcl-XL,life-long infection with resistance to CTL recognition by
inhibition of peptide transport from the cytosol into the or by the proapoptotic effectors, bad, bax, or bak. Both
death receptor and mitochondria pathways share aendoplasmic reticulum (ER) where MHC class I/peptide
complexes are assembled. The inhibition is mediated common set of caspases that cleave specific cellular
substrates, leading to DNA fragmentation, the hallmarkby the infected cell protein 47 (ICP47) (York et al., 1994),
which prevents peptide loading of MHC class I mole- of apoptosis. Viruses can block one or both pathways.
For instance, Kaposi’s sarcoma-associated herpesvi-cules by directly inhibiting the function of TAP, the pep-
tide transporter that puts antigenic peptides into the rus (KSHV) encodes a viral inhibitor called vFLIP
(ORF71), which disrupts the recruitment of caspase 8ER. Similarly, human cytomegalovirus (HCMV) interferes
with the MHC class I pathway using genes from the to FADD (Fas-associated death domain) to form the
death-inducing signaling complex (DISC). If caspase 8unique short (US) region of HCMV such as US2, 3, 6,
and 11 (reviewed in Tortorella et al., 2000). These gene is not included in the DISC, cell death triggered by death
receptors such as Fas is inhibited (Thome et al., 1997).products can independently block TAP-mediated pep-
tide translocation (US6), dislocate MHC class I heavy In addition, KSHV encodes a gene, ORF16, that is highly
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Figure 1. Evasion of Immune Responses by Viruses in Human
Three major mechanisms used by viruses to evade immune responses in human are illustrated. These include antigen presenting pathway
(MHC class I molecule/peptide complex), death receptors, and death-inducing ligands. DD, death domain; HIV, human immunodeficiency
virus; HCMV, human cytomegalovirus; HSV, herpes simplex virus; KSHV, Kaposi’s sarcoma-associated herpesvirus; HTLV-1, human T cell
leukemia virus type 1; EBV, Epstein-Barr virus.
homologous to endogenous bcl-2 and is able to sup- nalization of Fas from the cell surface and forces its
degradation inside lysosomes. This allows the infectedpress bax induction apoptotic signaling (Sarid et al.,
1997). Recently, the HIV-1 nef gene has been found to cells to resist Fas-mediated cell death and promotes
their survival (Tollefson et al., 1998). Perforin-deficientinhibit Fas and TNF receptor-mediated apoptosis of HIV-
1-infected cells by binding directly to and blocking the CTL are unable to lyse Adenovirus-infected cells but
can kill cells infected with virus that has a deletion offunction of ASK1 (the apoptosis-signal-regulating ki-
nase 1) (Geleziunas et al., 2001). ASK1 is a member of the E3 proteins.
the mitogen-activated protein 3 (MAPK3) family and can
activate the c-Jun NH2-terminal kinase pathway, which Counterattack
There are therefore many examples of viruses that avoidleads to apoptosis. More recently, Nef has been shown
to inactivate the proapoptotic protein bad by phosphor- CTL responses and resist apoptosis, prolonging the life
of the infected cells in the host. In some cases, despiteylation and consequently blocks the mitochondria-
induced apoptotic pathway (Wolf et al., 2001). Therefore, strong CTL responses in acute infection, the virus can
lead to generalized immunosuppression, for instanceHIV-1 nef can block both apoptotic pathways. Adenovi-
rus uses a different mechanism to protect infected cells HIV-1, measles, or certain strains of lymphocytic chorio-
meningitis virus (LCMV). In the case of HIV, this leadsfrom apoptosis. The E3-10.4/14.5K protein causes inter-
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to an impaired CTL response at the late stage of disease. can stimulate DC to upregulate TRAIL expression
This is associated with, though not necessarily caused (Fanger et al., 1999; Liu et al., 2001), so an indirect
by, widespread apoptosis in T cells (Meyaard et al., pathway is possible.
1992). As the majority of apoptotic cells are not HIV There are now many examples of how viruses subvert
infected (Finkel et al., 1995) this apoptosis could include the immune responses (Figure 1). It should be noted
HIV-specific CTL. In this issue of Immunity, Mueller et that the idea of counterattack mediated by FasL has
al. have compared the susceptibility of HIV- and CMV- yielded some conflicting results in models of tumor and
specific CTL to Fas-mediated apoptosis. Interestingly, autoimmune disease. Originally, it was thought that FasL
they found that HIV-specific CTL were more prone to might contribute to immune privilege in tissues like testis
apoptosis induced by anti-Fas antibody than CMV-spe- or eye and in some tumors by killing attacking CTL
cific CTL from the same patient (Mueller et al., 2001). (O’Connell et al., 2001). However, tumors engineered to
This was further confirmed by coculture of HIV-specific express FasL were rejected faster than their parent cells
CTL with macrophages infected with HIV-1, which in- (Favre-Felix et al., 2000). Similarly, induction of FasL
duces surface expression of FasL (Badley et al., 1996). expression on islet cells resulted in severe diabetes in
Why are HIV- but not CMV-specific CTL, which express an animal model (Chervonsky et al., 1997). Therefore,
comparable levels of Fas on the cell surface, more sensi- FasL expression may stimulate inflammation rather than
tive to Fas-mediated killing? Mueller et al. showed HIV- immune privilege, although the balance between FasL-
specific CTL were mainly CD45RACD62LCD8 T mediated inflammation and immune privilege could dif-
cells, whereas most CMV-specific CTL had a terminally fer in different tissues. It would probably not be to the
differentiated phenotype (CD45RACD62LCD8). To- advantage of a virus such as HIV or HCMV to provoke
gether with studies of Champagne et al. (2001) and Ap- a strong inflammatory response through induction of
pay et al. (2000), these data suggest that HIV skews FasL and TRAIL expression.
maturation of HIV-specific CTL, making them more vul- Whether or not the counterattack hypothesis is impor-
nerable to Fas-mediated apoptosis. HIV nef induces tant in virus infections needs to be addressed in vivo,
FasL expression on infected cells, and these can there- where the effects of particular death-inducing ligands
fore counterattack by killing the CTL through the Fas- could be blocked. Such studies will not only provide
FasL interaction (Xu et al., 1997). Furthermore, cross- new insights into virus and host interactions but may
linking of CD4 by HIV envelope protein (gp120) in the also lead to the discovery of new strategies for the treat-
presence of the HIV tat protein may also induce FasL ment of persistent viruses such HIV, HCMV, and EBV.
expression and apoptosis of uninfected CD4 T cells
(Westendorp et al., 1995). Additionally, interaction of HIV
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